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HSV-2 glycoprotein gD targets the CC
domain of tetherin and promotes tetherin
degradation via lysosomal pathway
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Abstract
Background: HSV-2 is the major cause of genital herpes. We previously demonstrated that the host viral restriction
factor tetherin restricts HSV-2 release and is antagonized by several HSV-2 glycoproteins. However, the mechanisms
underlying HSV-2 glycoproteins mediated counteraction of tetherin remain unclear. In this study, we investigated
whether tetherin restricts the cell-to-cell spread of HSV-2 and the mechanisms underlying HSV-2 gD mediated
antagonism of tetherin.
Methods: Infectious center assays were used to test whether tetherin could affect cell-to-cell spread of
HSV-2. Coimmunoprecipitation assays were performed to map the tetherin domains required for HSV-2
gD-mediated downregulation. Immunoflurence assays were performed to detect the accumulation of
tetherin in lysosomes or proteasomes. All experiments were repeated for at least three times and the data were
performed statistical analysis.
Results: 1) Tetherin restricts cell-to-cell spread of HSV-2; 2) HSV-2 gD specifically interacts with the CC domain of
tetherin; 3) HSV-2 gD promotes tetherin to the lysosomal degradation pathway.
Conclusions: Tetherin not only restricts HSV-2 release but also its cell-to-cell spread. In turn, HSV-2 gD targets the
CC domain of tetherin and promotes its degradation in the lysosome. Findings in this study have increased our
understanding of tetherin restriction and viral countermeasures.
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Background
Tetherin is an interferon (IFN)-inducible innate re-
striction factor involved in the host defense against
the release of envelope viruses [1, 2]. Based on the
deduced amino acid sequence, tetherin is character-
ized as a type II membrane protein with a Mr of ap-
proximately 24 kDa, while its mature form is a 30-
36-kDa, heterogeneously glycosylated, dimeric, type II
integral membrane protein, presumably due to hetero-
geneity of glycosylation during post-translational
modification, comprising a small cytoplasmic tail (CT)
domain, a trans-membrane (TM) domain, a glycopho-
sphatidylinositol (GPI) membrane anchor at the C-
terminus, and a long disulfide-rich coiled coil struc-
ture (CC) predicted for the extracellular domain [3, 4].
The mechanism by which different viruses counteract
tetherin is distinct. To date, a number of viral pro-
teins including Vpu and Env of HIV, Env and Nef of
SIV, K5 of KSHV, Ebola GP, gM/VHS of HSV-1 and
gB/gD/gH/gL of HSV-2 have been revealed to coun-
teract the restrictive properties of tetherin [1, 5–12].
Except a recent report that Ebola GP may overcome
tetherin restriction by blocking an interaction between
VP40 and tetherin [13], the counteraction generally
depends on the interaction between an viral antagon-
ist and a specific domain of tetherin [14]. For in-
stance, HIV-1 Vpu targets the TM domain of tetherin
for the subsequent antagonism of tetherin function
[1, 2, 15–19]; HIV-2 and tantalus SIV (SIVtan) Env
interacts with the ectodomain of tetherin [20, 21],
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while other SIVs employ the Nef protein to target the
cytoplasmic domain of tetherin [6, 8, 22]. The mech-
anisms underlying HIV-1 counteracts tetherin have
been intensively investigated, but less attention has
been paid to understanding those mediated by other
viruses.
Herpes simplex virus 2 (HSV-2) is a DNA virus
sexually transmitted and causes persistent infection
that cannot be eliminated [23]. HSV-2 is the leading
cause of genital ulcer disease (GUD) throughout the
world and associated with human immunodeficiency
virus 1 (HIV-1) acquisition [24–28]. HSV-2 transmis-
sion occurs via cell-free and direct cell-to-cell spread
[29]. The HSV-2 glycoprotein D (gD), a major com-
ponent of the virion envelope, was previously revealed
to be essential for viral fusion and plays an important
role in the cell-to-cell spread of the virus in permis-
sive cells [30, 31].
Our previous study has revealed that tetherin func-
tions as a restriction factor to inhibit HSV-2 release and
that several glycoproteins including gD downregulate
the expression of tetherin [11]. In this study, we investi-
gated whether tetherin restricts the cell-to-cell spread of
HSV-2 and the mechanisms underlying HSV-2 gD medi-
ated antagonism of tetherin.
Results
Tetherin restricts cell-to-cell spread of HSV-2
Spread of HSV-2 progeny virus can occur both by re-
lease of mature infectious virus particles into the extra-
cellular medium and by viral cell-to-cell spread. Having
demonstrated that the release of cell-free HSV-2 pro-
geny virions was restricted by tetherin [11], we further
asked whether tetherin could affect cell-to-cell spread of
HSV-2 by using infectious center assay. Firstly, the
plaque formation on HeLa monolayer with or without
anti-HSV-2 antibody treatment was tested. The area of
plaques was relatively uniform in the presence of anti-
HSV-2 antibody, while some small spots existed in the
samples without anti-HSV-2 antibody (Fig. 1a and b).
The following experiments were all performed under the
anti-HSV-2 antibody treatment. Subsequently, the HeLa
monolayers pretreated with tetherin or control siRNA
were examined. Western blot analysis indicated that
siRNA knockdown of tetherin efficiently reduced the ex-
pression of tetherin (Fig. 1c). As shown in Fig. 1d and e,
compared to control siRNA-pretreated HeLa cells, the
plaque size was modestly increased upon tetherin siRNA
pretreatment. Accordingly, two polarized epithelial cell
types (HaCaT and ARPE-19) [32, 33] were used in the in-
fectious center assay. As shown in Fig. 1f and g, the plaque
size was significantly reduced on the pBST2 transfected
HaCaT and ARPE-19 monolayers, confirming an interfer-
ence with the cell-to-cell spread of HSV-2 in the presence
of tetherin. Taken together, the reduced size of HSV-2 pla-
ques by tetherin informs that tetherin at least partially in-
hibits the direct cell-to-cell spread of HSV-2 during
plaque formation.
HSV-2 gD specifically interacts with the CC domain of
tetherin
The interaction between HSV gD expressed in the pro-
geny virus producing cells and the neighbouring host
cells is essential for cell-to-cell spread. We previously
demonstrated that several glycoproteins of HSV-2, in-
cluding gD, can downregulate the expression of tetherin.
To map the tetherin domains required for HSV-2 gD-
mediated downregulation, we constructed a panel of de-
letion mutants of tetherin (Fig. 2a) and performed
coimmunoprecipitation assays using cells transiently ex-
pressing wild type tetherin or its mutants. The expres-
sion of tetherin mutants was confirmed by western blot
using an anti-tetherin antibody (Fig. 2b). Subsequently,
the precleared cell lysates from the transfected cells were
incubated with an anti-flag antibody or an isotype con-
trol antibody. The precipitates were analyzed by western
blot using the antibody against tetherin. The tetherin
mutants delTM, delCT and delGPI but not delCC were
specifically coimmunoprecipitated by the flag antibody
(Fig. 2c, d, e and f, left panels). Co-IP experiments were
also performed by pulling down with the antibody
against tetherin followed by western blot with the flag
antibody. The antibody against tetherin was able to
specifically precipitate the immune complexes that con-
tained gD-flag and delTM, delCT or delGPI (Fig. 2c, d,
e and f, right panels), indicating that only the CC do-
main of tetherin is required for the physical interaction
with HSV-2 gD. Taken together, these data suggest that
tetherin is down-regulated through a specific inter-
action between HSV-2 gD and the CC domain of
tetherin.
HSV-2 gD promotes tetherin to the lysosomal degradation
pathway
The known antagonists of tetherin can lead the degrad-
ation of tetherin in late endosomes, lysosomes or protea-
somes [34]. To examine whether the gD mediated-
downregulation of tetherin undergoes lysosomal or
proteasomal degradation pathway, HeLa cells were
transfected with pcDNA3.1 or gD expressing plasmid
followed by cultivation in the presence of a mixture of
lysosome protease inhibitors (LPI; containing leupeptin,
pepstatin A, and E64d) or the proteasome protease in-
hibitor (PPI; containing MG132). The paralleled HeLa
cells transfected with gM expressing plasmid were in-
cluded as the control. At 24 hours post transfection,
cells were processed for immunofluorescence staining
for subcellular localization of tetherin, gD/gM and a
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lysosome marker cathepsin D or a proteasome marker
20S proteasome. As shown in Fig. 3a and c, colocaliza-
tion of gD, tetherin and cathepsin D was seen in gD ex-
pressing cells treated with lysosomal protease inhibitors,
whereas tetherin and cathepsin D did not apparently
colocalize in the pcDNA3.1- or gM-transfected cells.
Tetherin colocalized with the 20S proteasome in the
presence or absence of HSV-2 gD (Fig. 3b and d), imply-
ing that tetherin likely physiologically undergoes protea-
somal degradation in the absence of HSV-2 gD. Western
blot assay demonstrated that the lysosome protease in-
hibitors (LPI) rescued tetherin from degradation in the
gD-transfected cells (Fig. 3e). To confirm that the gD
mediated-downregulation of tetherin undergoes lyso-
somal degradation, we used a lysosome enrichment kit
(Thermo) to isolate and enrich the intact lysosomes
from cells transfected with pcDNA3.1 or plasmids ex-
pressing gD. The prepared cell extract was ultracentri-
fuged by density gradient centrifugation. We collected
the corresponding band and detected the finally har-
vested lysosome pellets by western blot. As shown in
Fig. 3f, the lysosome marker LAMP1, tetherin and gD all
existed in the separated samples from gD-transfected
cells. In contrast, only LAMP1 existed in the samples
from pcDNA3.1 transfected cells. These data together in-
dicate that the gD mediated-downregulation of tetherin
undergoes lysosomal degradation.
Discussion
Tetherin has been shown to inhibit viral release and dir-
ect cell-to-cell spread of HIV-1 [35–37]. However,
whether tetherin restricts cell-to-cell spread of other
Fig. 1 Tetherin restricts cell-to-cell spread of HSV-2. HeLa cells were infected with HSV-2 using 0.0001PFU/cell. Two hours later, the virus inoculum
was removed and cells were incubated in the medium containing anti-HSV-2 antibody a or incubated in the normal medium without anti-HSV-2
antibody b. After 2 days, the cells in a and b were fixed and stained for HSV-2 antigens. The peroxidase-conjugated secondary antibody and
substrate were used to reveal HSV-2-infected cells. c The expression of total tetherin in HeLa cells pretreated with tetherin siRNA or control siRNA
was analyzed by western blot where actin was used as a loading control. Molecular weight standards in kilodalton are shown on the left. d and e
The morphology of HSV-2 plaques on HeLa monolayers pretreated with tetherin siRNA d or control siRNA e. Representative fields observed in
four experiments are shown. f The morphology of HSV-2 plaques on HaCaT and ARPE-19 monolayers transfected with pcDNA3.1 or pBST2 using
the infectious center assay as described in the Materials and Methods. Representative morphology of HSV-2 plaques on HaCaT and ARPE-19
monolayers are shown. Scale bars in all panels represent 100 μm. g Representative fields containing more than 10 plaques were chosen and the
plaque areas were calculated. The plaque area of the pcDNA3.1-transfected cells was arbitrarily set at a value of 100 for comparison with that of
the pBST2-transfected cells. Data shown are mean ± SD
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viruses is less clear. We previously showed that tetherin
restricts viral release of HSV-2. Here we demonstrate
that tetherin restricts the cell-to-cell spread of HSV-2,
suggesting that such restriction may be physiologically
relevant for viruses that are capable of cell to cell trans-
mission. Interestingly, HSV-1 can use heparan sulfate
(HS) as an entry receptor for infection of host cells [38].
However, during a productive infection, the HS moieties
on parent cells can trap newly exiting viral progenies
and inhibit their release and cell to cell spread. It has
been revealed that heparanase (HPSE), a HS-degrading
enzyme of the host, can translocate to the cell surface
upon HSV-1 infection, leading to the removal of HS to
facilitate viral release [39]. In agreement, potent HPSE
inhibitor can successfully decrease cell-to-cell spread of
HSV-1 and HSV-2 [40]. Although beyond the scope of
this current study, it will be interesting to determine
whether there is a similar enzyme or mechanism which
can degrade tetherin to aid virus egress.
To counteract host restriction, viruses have evolved vari-
ous evasion strategies. For instance, although tetherin effi-
ciently inhibits the release of a number of enveloped virus
particles by “tethering” them to the cell surface, different
viral antagonists employ different mechanisms to counter-
act the restriction by tetherin. Current understanding how
viruses counteract the restrictive property of tetherin is
largely limited to the findings from retroviruses. In gen-
eral, the counteraction is dependent of the interaction be-
tween viral antagonists and different domains of tetherin
[14]. In the current study, we demonstrated that HSV-2
gD specifically interacts with the CC domain of tetherin.
There are several proposed mechanisms for the final
fate of tetherin, including lysosomal degradation, protea-
somal degradation, and/or sequestration/retargeting of
tetherin to the trans-Golgi network [16, 21, 41–44]. Our
previous study demonstrated that the levels of cell sur-
face and total cellular tetherin were decreased in the
presence of HSV-2 glycoproteins, implying that tetherin
is likely counteracted by viral glycoproteins via a degrad-
ation pathway. In the current study, immunofluores-
cence images revealed that tetherin colocalized with the
lysosome marker cathepsin D in the presence of HSV-2
gD, and western blot assay showed that gD and tetherin
exist in the isolated lysosomes of gD-transfected cells,
suggesting that gD promotes the degradation of tetherin
in lysosomal pathway. Surprisingly, we found that the
Fig. 2 The CC domain of tetherin is specifically recognized by HSV-2 gD. a Schematic representation of full-length and deletion mutants of
tetherin. The cDNAs of full-length human tetherin and its deletion mutants were cloned into pcDNA3.1(−), respectively. The TM, CC, and GPI
domains of tetherin are represented in blue. b Expressions of WT and tetherin mutants were confirmed by western blot using the anti-tetherin
polyclonal antibody. c-f Co-immunoprecipitation assays (co-IP) were performed by using the antibodies against tetherin and flag. The tetherin
mutants delTM, delCT, delGPI and delCC were cotransfected with gD-flag into 293 T cells, respectively. The lysates were coimmunoprecipitated by
the flag antibody and then western blot for tetherin (left panels) or coimmunoprecipitated by the tetherin antibody and then western blot for
flag (right panels). c The interaction of gD-flag and the delCT. d The interaction of gD-flag and the delTM. e The interaction of gD-flag and the
delGPI. f The interaction of gD-flag and the delCC
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colocalization of tetherin and proteasome marker 20S
proteasome was independent of the presence of gD, sug-
gesting that tetherin itself, at least in HeLa cells, may
physiologically undergo proteasomal degradation in the
absence of HSV-2 gD. Although we cannot exclude
other possibility, one possible explanation is that the
proteasomal degradation may be cell-type dependent.
Conjugation of proteins to ubiquitin is the hallmark of
26S proteasome mediated degradation, which is com-
posed of a central 20S core containing catalytic subunits.
The colocalization of tetherin and 20S proteasome im-
plies the involvement of ubiquitinylation. Our data to-
gether demonstrated that tetherin indeed undergoes the
lysosomal degradation in the presence of HSV-2 gD.
Conclusions
We demonstrate that tetherin not only inhibits HSV-2
release but also restricts its cell-to-cell spread. In turn,
HSV-2 gD targets the CC domain of tetherin and pro-
motes its degradation in the lysosome. Findings in this
study have increased our understanding of tetherin re-
striction and viral countermeasures.
Methods
Virus and cells
Human cervical epithelial cell line HeLa, human kera-
tinocyte cell line HaCaT, African green monkey kidney
cell line Vero and embryonic kidney cell line 293 T
were grown in Dulbecco’s modified Eagle’s medium
(DMEM; Gibco) containing 10 % FBS, 100 Units/ml
penicillin and 100 Units/ml streptomycin at 37 °C in
5 % CO2. Human retinal pigment epithelial cell line
ARPE-19 was grown in DMEM/F-12 medium (50:50)
supplemented with 10 % FBS, 100 Units/ml penicillin
and 100 Units/ml streptomycin at 37 °C in 5 % CO2.
HSV-2 (G strain) was obtained from LGC standards
and propagated in Vero cells. Virus stock was stored at
−80 °C before used for infection.
Plasmids
The open reading frames (ORF) of human tetherin
amplified from pBST2 (Origene) was subcloned into
pcDNA3.1(−) to construct the plasmid pWT (expressing
full-length human tetherin). A panel of deletion mutants
of tetherin were made and subcloned into pcDNA3.1(−),
named delCT expressing 20–180 aa of human tetherin,
delTM expressing 45–180 aa of human tetherin, delCC
expressing human tetherin with the deleption of 100–
154 aa and delGPI expressing 1–161 aa of human
tetherin, respectively. The delTM without secretory
leader peptide is not efficient for tetherin mutant to an-
chor on the cell surface membrane, we therefore fused
the secretory leader peptide MDAMKRGLCCVLLLC
GAVFVSPSQE from tissue plasminogen activator to
tetherin codons 45–180 as described previously [45].
The glycoprotein gD and gM fused to flag tag were
cloned into pcDNA3.1 (+) (named pgD-flag and pgM-
flag) as described previously. The construction, cloning
and propagation of plasmids were carried out using
standard techniques. All constructs were verified by
DNA sequencing (Sunny Biotechnology Co. Ltd,
Shanghai, China).
siRNA mediated knockdown of tetherin
Tetherin siRNAs (SI02777054) and control siRNA
(1027281) were purchased from Qiagen. HeLa cells were
plated onto 6-well culture dishes overnight. Hela mono-
layers were transfected with tetherin siRNA or control
siRNA using HiPerFect Transfection Reagent (301704;
Qiagen) according to the manufacturer's instructions.
Infectious center assay
Infectious center assay was carried out as previously de-
scribed [46]. In brief, HeLa, HaCaT and ARPE-19 cells
plated in 6-well plates at 50 % confluence were exposed
to HSV-2 at an MOI of 5 at 37 °C. After 90 min of incu-
bation, cells were washed once with PBS and then
treated with 0.1 M citrate buffer (pH 3.0) for 1 min to
(See figure on previous page.)
Fig. 3 HSV-2 gD downregulates tetherin via lysosomal pathway. a HeLa cells transfected with pcDNA3.1 or plasmid expressing gD-flag/gM-flag
were costained with anti-flag (red), anti-tetherin (purple) and anti-cathepsin D (green) antibodies. Nuclei were counterstained with Hoechst 33258
(blue). The colocalization of tetherin with lysosome markers (cathepsin D) was assessed by confocal microscopy. Representative confocal images
from three independent experiments are shown. Scale bars in all panels represent 10 μm. b HeLa cells transfected with pcDNA3.1 or plasmid
expressing gD-flag/gM-flag were costained with anti-flag (red), anti-tetherin (purple) and anti-20S proteasome (green) antibodies. Nuclei were
counterstained with Hoechst 33258 (blue). The colocalization of tetherin with the proteasome markers (20S proteasome) was assessed by confocal
microscopy. Representative confocal images from three independent experiments are shown. Scale bars in all panels represent 10 μm. c Pearson’s
correlation coefficients were analyzed to determine the colocalization of tetherin and cathepsin D. d Pearson’s correlation coefficients were
analyzed to determine the colocalization of tetherin and 20S proteasome. Data shown are mean ± SD by quantitative analyses of at least 20 distinct
cells. e Western blot was used to analyze the expression of total tetherin in HeLa cells transfected with control plasmid and plasmid expressing gD-flag
(treated or untreated with lysosome protease inhibitors (LPI)) where actin was used as a loading control. f HeLa cells transfected with pcDNA3.1 or
plasmid expressing gD-flag were treated by lysis buffer. The prepared cell extract was ultracentrifuged by density gradient centrifugation and the
lysosome band is located in the top 2 mL of the gradient. The corresponding bands were collected and the finally harvested lysosome pellets were
detected by western blot. Samples 1 and 2 were two finally harvested lysosome pellets in two representative experiments
Liu et al. Virology Journal  (2016) 13:154 Page 6 of 9
inactivate extracellular virus particles. The monolayer
was then washed twice with PBS to remove the low-pH
buffer, and cells were placed in growth medium supple-
mented with anti-HSV-2 antibody (PAB13979; Abnova)
at a dilution of 1:1000 to neutralize extracellular HSV-2.
After a total incubation of 5.5 h, the infected cells were
detached with trypsin-EDTA, resuspended in growth
medium, and ~100 cells were plated onto 50 % confluent
monolayers of uninfected HaCaT and ARPE-19 cells
transfected with pBST2 or pcDNA3.1, or of uninfected
HeLa cells pretreated with tetherin or control siRNA.
Cells were maintained in growth medium containing
anti-HSV-2 polyclonal antibody. After 2 days, the cells
were fixed and stained for HSV-2 antigens, followed by
the addition of the peroxidase-conjugated secondary
antibody and substrates. Plaques were photographed and
the plaque areas were compared.
Co-immunoprecipitation
Co-immunoprecipitation assay was carried out using
Pierce Crosslink Immunoprecipitation Kit (26147; Thermo
scientific) according to the manufacturer's instructions.
For co-immunoprecipitations of gD-flag and tetherin mu-
tants, mouse monoclonal antibody against FLAG (F1804;
Sigma) and rabbit polyclonal antibody to tetherin (11721;
NIH AIDS Research and Reference Reagent Program)
were used for pull-down experiments. These two anti-
bodies were also used for western blot analysis of the im-
munoprecipitates and the lysates.
Western blot
Prepared cell lysates were resolved by 12 % SDS-
PAGE and transferred to 0.45 μm polyvinylidene
difluoride membranes (Millipore). Nonspecific binding
was blocked using 5 % non-fat milk in PBS overnight at
4 °C. The membrane was incubated with primary anti-
body against tetherin (rabbit polyclonal antibody;
11721; NIH AIDS Research and Reference Reagent Pro-
gram) at a dilution of 1:5000, FLAG (mouse monoclo-
nal antibody; F1804; Sigma) at a dilution of 1:3000, and
β-actin (mouse monoclonal antibody; sc-81178; Santa
Cruz) at a dilution of 1:500, for 1 h at 37 °C. The mem-
brane was washed five times with 0.1 % Tween 20/PBS,
followed by incubation for 1 h with HRP conjugated
goat anti–rabbit secondary antibody (1:10,000; BA1054,
Boster) or HRP conjugated goat anti–mouse secondary
antibody (1:10,000; BA1050, Boster). After five washes
with 0.1 % Tween-20/PBS, the bands were visualized by
exposure to FluorChem HD2 Imaging System (Alpha
Innotech) after the addition of chemiluminescent sub-
strate (SuperSignal® West Dura Extended Duration Sub-
strate; 34075; Thermo Scientific Pierce).
Immunofluorescence
To detect the accumulation of tetherin in lysosomes or
proteasomes, transfected cells were cultured in complete
medium in the presence of a mixture of lysosome prote-
ase inhibitors (containing leupeptin, pepstatin A and
E64d; Sigma) for 16 h or a proteasome inhibitor
(MG132; Sigma) for 12 h as previously described [16].
Transfected cells on 35 mm glass bottom culture dishes
were washed twice with phosphate-buffered saline (PBS),
followed by fixation with 4 % (w/v) cold paraformalde-
hyde for 30 min at room temperature. Cells were perme-
abilized with PBST (PBS-0.2 % (v/v) Triton X-100) for
10 min at room temperature and then blocked with
PBS-2 % (w/v) BSA for 1 h at room temperature. Cells
were incubated for 1 h at 37 °C with mouse monoclonal
antibody against FLAG (F1804; Sigma) at a dilution of
1:200 and followed by incubation for 1 h at 37 °C with
Cy3-conjugated goat anti-mouse secondary antibody
(Beyotime, China) at a dilution of 1:200 in PBS-2 % (w/
v) BSA. Thereafter, cells were incubated for 1 h at 37 °C
with mouse monoclonal antibody against tetherin
(H00000684-M15, Abnova) at a dilution of 1:200 and
rabbit polyclonal antibody against cathepsin D (sc-
10725; Santa Cruz) (or 20S proteasome α7/α8 (sc-67344;
Santa Cruz)) at a dilution of 1:100 in PBS-2 % (w/v) BSA,
followed by incubation for 1 h at 37 °C with Cy5-
conjugated goat anti-mouse secondary antibody (Beyo-
time, China), FITC-conjugated goat anti-rabbit secondary
antibody (Beyotime, China) at a dilution of 1:200 in PBS-
2 % (w/v) BSA. Cells were washed three times after each
incubation with PBS and then twice with distilled water.
Nuclei were dyed by Hoechst 33258 (Invitrogen). Stained
cells were analyzed using confocal microscopy (PerkinEl-
mer UltraView VoX).
Statistical analysis
All experiments were repeated for at least three times.
Data are presented as mean ± SD unless otherwise speci-
fied. The difference of mean value was analyzed by a
paired Student’s t-test. P < 0.05 was considered statisti-
cally significant.
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